Adults 18 to 99, any sex, with COVID-19 or SARS-CoV 2. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent of Healthcare Workers Testing Positive for COVID-19.Primary· 3 weeks
Percent of healthcare workers that become positive for COVID-19 during the study.
Group
Value
95% CI
Healthcare Workers - Control
0
Healthcare Workers - PVP-I
0
Percent of Patients Testing Positive for COVID-9.Primary· 2 weeks
Percent of patients that become positive for COVID-19 during the study.
Group
Value
95% CI
Inpatients - Control
0
Inpatients - PVP-I
0
Percent of Community Participants Testing Positive for COVID-9.Primary· 3 weeks
Percent of community participants that become positive for COVID-19 during the study.
Group
Value
95% CI
Community - Control
0
Community - PVP-I
0
PVP-I Ease of UseSecondary· 3 weeks
Patients will rate the ease of use for PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased ease of use (1="easy") while higher scores indicate increased difficulty (5="impossible").
Group
Value
95% CI
Healthcare Workers - PVP-I
4.48
± 0.80
Inpatients - PVP-I
4.43
± 0.85
Community - PVP-I
4.77
± 0.44
PVP-I ComfortSecondary· 3 weeks
Patients will rate the comfort of PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased comfort (1="not so bad") while higher scores indicate discomfort (5="worst pain of my life").
Group
Value
95% CI
Healthcare Workers - PVP-I
3.25
± 1.33
Inpatients - PVP-I
4.00
± 1.41
Community - PVP-I
3.00
± 1.53
Sponsor's own description
Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Staphylococcus Aureus (MRSA) as well as oral preparations in in-vitro studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), influenza H1N1, and rotavirus with good efficacy. This study will evaluate the efficacy of PVP-I as prophylaxis in Coronavirus Disease 2019 (COVID19)-negative front-line health care workers, hospital patients, and community members.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
· Phase 1
· active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
· Phase 3
· active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
· Phase 1
· recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
· Phase 2
· recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A
· Phase 3
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nikita Gupta
Last refreshed: 2 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04364802.